Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a first-in-human study in patients with advanced cancer presented at this year’s virtual ASCO.
Read here: https://meetinglibrary.asco.org/record/185085/abstract
Advertisement